Form 4: Intra-Cellular Therapies CEO Sharon Mates Reports Stock Transactions

Sharon Mates, CEO of Intra-Cellular Therapies, reports acquisition of shares through vested performance-based restricted stock units and withholding of shares for tax obligations.

Summary

• On January 31, 2025, Sharon Mates, CEO of Intra-Cellular Therapies, acquired 30,847 shares of common stock through the vesting of performance-based restricted stock units (PRSUs).
• These PRSUs were granted on March 10, 2022, under the company's equity incentive plan.
• Also on January 31, 2025, 15,233 shares were withheld by the issuer to cover tax obligations related to the vesting of the PRSUs at a price of $127.
• On February 3, 2025, Mates was granted 121,212 restricted stock units (RSUs) that vest in three equal annual installments starting on the first anniversary of the grant date.
• Following these transactions, Mates directly owns 1,085,943 shares of common stock and 121,212 restricted stock units.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing related to stock transactions. The vesting of PRSUs suggests positive performance, but the tax withholding is a neutral event.

Positives

• The vesting of performance-based restricted stock units for the CEO suggests achievement of performance criteria.

Negatives

• The withholding of shares to cover tax obligations reduces the number of shares directly held by the CEO.

Future Outlook

The 121,212 restricted stock units granted on February 3, 2025, will vest in three equal annual installments starting on the first anniversary of the grant date.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's confidence and actions regarding the company's stock.

Comparison to Industry Standards

• Stock-based compensation is a common practice in the pharmaceutical industry to align management's interests with those of shareholders.
• Companies like Amgen, Biogen, and Gilead Sciences also utilize restricted stock units and performance-based awards as part of their executive compensation packages.
• The vesting schedules and performance criteria for these awards vary across companies and are often tied to specific milestones or financial targets.

Stakeholder Impact

• Shareholders may view the vesting of PRSUs as a positive sign, indicating that the CEO has met certain performance criteria.
• Employees may be motivated by the company's use of equity incentives to align their interests with the company's success.

Key Dates

Keywords

Form 4, Insider Trading, Restricted Stock Units, Performance-Based Restricted Stock Units, Equity Incentive Plan, Beneficial Ownership, Intra-Cellular Therapies, ITCI, Sharon Mates